Cogent Biosciences, Inc.

NASDAQ:COGT

10.05 (USD) • At close November 7, 2024
Bedrijfsnaam Cogent Biosciences, Inc.
Symbool COGT
Munteenheid USD
Prijs 10.05
Beurswaarde 1,099,972,500
Dividendpercentage 0%
52-weken bereik 3.67 - 12.61
Industrie Biotechnology
Sector Healthcare
CEO Mr. Andrew R. Robbins M.B.A.
Website https://www.cogentbio.com

An error occurred while fetching data.

Over Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in

Vergelijkbare Aandelen

KalVista Pharmaceuticals, Inc. logo

KalVista Pharmaceuticals, Inc.

KALV

11.18 USD

VistaGen Therapeutics, Inc. logo

VistaGen Therapeutics, Inc.

VTGN

3.12 USD

VBI Vaccines Inc. logo

VBI Vaccines Inc.

VBIV

0.065 USD

Zentek Ltd. logo

Zentek Ltd.

ZTEK

1.25 USD

Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated

PRLD

1.27 USD

bluebird bio, Inc. logo

bluebird bio, Inc.

BLUE

0.382 USD

Viemed Healthcare, Inc. logo

Viemed Healthcare, Inc.

VMD

9 USD

MacroGenics, Inc. logo

MacroGenics, Inc.

MGNX

4.46 USD

Singular Genomics Systems, Inc. logo

Singular Genomics Systems, Inc.

OMIC

23.3 USD

PepGen Inc. logo

PepGen Inc.

PEPG

5.63 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)